- ►diabetesjournals.org C Hohberg, T Forst, M Larbig, M Safinowski, S … - Diabetes Care, 2008 - Am Diabetes Assoc RESULTS—Insulin glulisine injections resulted in higher postprandial insulin levels (means
± SEM area under the curve [AUC] 0–120 51.0 ± 6.8 vs. 38.2 ± 5.4 mU/l; P = 0.004), while plasma
glucose (AUC 0–240 158 ± 9 vs. 180 ± 9 mg/dl; P < 0.05) and intact proinsulin (AUC ... Cited by 5 - Related articles - BL Direct - All 5 versions
S Luzio, R Peter, GJ Dunseath, L Mustafa, DR … - Diabetes Research and …, 2007 - Elsevier Overall, preprandial-subtracted glucose concentrations (area under the curve) were similar on
the glulisine and lispro study days. However, the mean of the three maximal preprandial subtracted
plasma glucose concentrations (ΔGLU max ) were lower with glulisine versus lispro ... Cited by 6 - Related articles - All 25 versions
K Horvath, G Bock, W Regittnig, M … - Diabetes, Obesity …, 2008 - interscience.wiley.com Methods: Eighteen patients with type 1 diabetes mellitus (mean age 36.9 ± 8.6 years, BMI 23.6
± 2.8 kg/m 2 , haemoglobin A 1c 7.4 ± 0.9%) were randomized in this single-centre,
double-blind, three-period cross-over, standard Latin-square, euglycaemic glucose clamp ... Cited by 3 - Related articles - All 3 versions
T Forst, S Forst, K Strunk, M Löbig, K Welter, C … - Journal of diabetes and its …, 2005 - Elsevier In this open-label, randomised cross-over study, 20 nondiabetic participants and 20 patients
with Type 1 diabetes were enrolled. To valuate the postprandial time course of skin microvascular
blood flow, laser Doppler flux (LDF) readings were obtained at baseline and every 30 min ... Cited by 6 - Related articles - All 14 versions
RHA Becker, AD Frick, L Nosek, L Heinemann, K … - Diabetes Care, 2007 - Am Diabetes Assoc Rapidly absorbed and acting insulin analogs are increasingly being used to improve postprandial
metabolic control (1), which may help in reducing cardiovascular-related and all-cause mortality
in patients who already have good metabolic control (A1C <8%) (2). Insulin glulisine is a ... Cited by 6 - Related articles - BL Direct - All 7 versions
KP Garnock-Jones, GL Plosker - Drugs, 2009 - ingentaconnect.com Various sections of the manuscript reviewed by: DSH Bell, Division of Endocrinology and
Metabolism, University of Alabama at Birmingham, Birmingham, Alabama, USA; BW Bode, Atlanta
Diabetes Associates, Atlanta, Georgia, USA; K. Kaku, Department of Medicine, Kawasaki ... Related articles - All 3 versions
F Schliess, T Heise - Therapy, 2009 - Future Medicine Insulin glulisine (glulisine) is a new fast-acting human insulin analogue approved for treatment
of diabetes Type 1 and 2. Preclinical investigations indicate mitogenic and metabolic potency
similar to human insulin, but distinct β-cell protective properties, possibly related to a ... Related articles - All 3 versions
P ITT, P PP - genesis.sefh.es Justificación de la solicitud: consigue un pico de acción claramente más rápìdo que la insulina
regular y discretamente más rápido que los análogos lispro y aspart, sobre todo en pacientes
obesos. No contiene Zinc. ... Conservación: viales cerrados en nevera (2º-8ºC); viales ... Related articles - View as HTML
S Fordan, P Raskin - Vascular Health and Risk Management, 2009 - pubmedcentral.nih.gov The insulin analogs lispro, aspart, and glulisine are the only commercially available rapid-acting
insulins to treat diabetes. We review the evidence for treating hyperglycemia, using insulin, and
specifically using rapid-acting analogs in diabetic individuals, on the prevention of ... Related articles - All 6 versions
